Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Novel mathematical approach reveals shared gene programs in anti-tumor CD8+ T cells July 2, 2024 High linoleic acid intake during pregnancy may harm fetal growth and raise obesity risk September 10, 2024 Blood test identifies specific pathologies in frontotemporal dementia, ALS, and PSP June 18, 2024
High linoleic acid intake during pregnancy may harm fetal growth and raise obesity risk September 10, 2024